Advanced Solid Tumor Clinical Trials in Madison, Wisconsin

5 studies are recruiting for advanced solid tumor in Madison, Wisconsin right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

   A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Wisconsin Health - UW Carbone Cancer Center, Madison, Wisconsin

   Locations

   21 in total

   Run by

   MediLink Therapeutics (Suzhou) Co., Ltd.

   See if you can join NCT06859762 on ClinicalTrials.gov

2. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

3. Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

   This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-T187 alone and in combination with other therapeutic agents in parti…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Washington University, St Louis, Division of Oncology, Madison, Wisconsin

   Locations

   34 in total

   Run by

   BeOne Medicines

   See if you can join NCT06598800 on ClinicalTrials.gov

4. A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

   This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either me…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Board of Regents of the University of Wisconsin, Madison, Wisconsin

   Locations

   76 in total

   Run by

   BioNTech SE

   See if you can join NCT07070232 on ClinicalTrials.gov

5. A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 alone and in combination with anticancer agents in participants with advanced solid tumors. The study will be conducted in two phases: Phase 1a (…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Wisconsin, Madison, Wisconsin

   Locations

   52 in total

   Run by

   BeOne Medicines

   See if you can join NCT06625593 on ClinicalTrials.gov